Genus (LON:GNS – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at Shore Capital in a research note issued to investors on Friday, MarketBeat Ratings reports. They presently have a GBX 3,000 price target on the stock. Shore Capital’s price target would indicate a potential upside of 7.30% from the company’s current price.
A number of other research analysts have also weighed in on the stock. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Genus from GBX 2,900 to GBX 3,100 and gave the company a “buy” rating in a research note on Wednesday, November 19th. Berenberg Bank boosted their price objective on Genus from GBX 3,050 to GBX 3,250 and gave the company a “buy” rating in a research note on Friday. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of GBX 3,116.67.
Read Our Latest Research Report on Genus
Genus Stock Performance
Genus Company Profile
Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands.
Read More
- Five stocks we like better than Genus
- 53% Gains In 4 Years. Then 51% In Under 11 Months.
- Is Elon Preparing for a Silver Shock?
- NEW LAW: Congress Approves Setup For Digital Dollar?
- Do not delete, read immediately
- The Crash Has Already Started (Most Just Don’t See It Yet)
Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with MarketBeat.com's FREE daily email newsletter.
